Metastatic adrenocortical carcinoma treated with sunitinib: A case report

Jeong Ok Lee; Keun Wook Lee; Chung Jong Kim; Yu Jung Kim; Hee Eun Lee; Haeryoung Kim; Jee Hyun Kim; Soo Mee Bang; Jae Sung Kim; Jong Seok Lee

doi:10.1093/jjco/hyn146

Metastatic adrenocortical carcinoma treated with sunitinib: A case report

Jeong Ok Lee, Keun Wook Lee, Chung Jong Kim, Yu Jung Kim, Hee Eun Lee, Haeryoung Kim, Jee Hyun Kim, Soo Mee Bang, Jae Sung Kim, Jong Seok Lee

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis. Palliative chemotherapy can be considered in patients with metastatic disease. Although mitotane- or cisplatin-based chemotherapy regimens are widely used, the effects of these agents have been limited. We have experienced a case that showed a partial response with sunitinib after failure of mitotane-based cytotoxic chemotherapy. The clinical benefit from sunitinib persisted 7.5 months in this case. To our knowledge, this is the first reported case showing the effects of sunitinib on metastatic ACC.

Original language	English
Pages (from-to)	183-185
Number of pages	3
Journal	Japanese Journal of Clinical Oncology
Volume	39
Issue number	3
DOIs	https://doi.org/10.1093/jjco/hyn146
State	Published - 2009

Keywords

Adrenocortical carcinoma
Chemotherapy
Sunitinib

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jjco/hyn146

Cite this

@article{e9dc2c186c7d4b19aafd0448805dcb6e,

title = "Metastatic adrenocortical carcinoma treated with sunitinib: A case report",

abstract = "Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis. Palliative chemotherapy can be considered in patients with metastatic disease. Although mitotane- or cisplatin-based chemotherapy regimens are widely used, the effects of these agents have been limited. We have experienced a case that showed a partial response with sunitinib after failure of mitotane-based cytotoxic chemotherapy. The clinical benefit from sunitinib persisted 7.5 months in this case. To our knowledge, this is the first reported case showing the effects of sunitinib on metastatic ACC.",

keywords = "Adrenocortical carcinoma, Chemotherapy, Sunitinib",

author = "Lee, {Jeong Ok} and Lee, {Keun Wook} and Kim, {Chung Jong} and Kim, {Yu Jung} and Lee, {Hee Eun} and Haeryoung Kim and Kim, {Jee Hyun} and Bang, {Soo Mee} and Kim, {Jae Sung} and Lee, {Jong Seok}",

year = "2009",

doi = "10.1093/jjco/hyn146",

language = "English",

volume = "39",

pages = "183--185",

journal = "Japanese Journal of Clinical Oncology",

issn = "0368-2811",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Metastatic adrenocortical carcinoma treated with sunitinib

T2 - A case report

AU - Lee, Jeong Ok

AU - Lee, Keun Wook

AU - Kim, Chung Jong

AU - Kim, Yu Jung

AU - Lee, Hee Eun

AU - Kim, Haeryoung

AU - Kim, Jee Hyun

AU - Bang, Soo Mee

AU - Kim, Jae Sung

AU - Lee, Jong Seok

PY - 2009

Y1 - 2009

N2 - Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis. Palliative chemotherapy can be considered in patients with metastatic disease. Although mitotane- or cisplatin-based chemotherapy regimens are widely used, the effects of these agents have been limited. We have experienced a case that showed a partial response with sunitinib after failure of mitotane-based cytotoxic chemotherapy. The clinical benefit from sunitinib persisted 7.5 months in this case. To our knowledge, this is the first reported case showing the effects of sunitinib on metastatic ACC.

AB - Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis. Palliative chemotherapy can be considered in patients with metastatic disease. Although mitotane- or cisplatin-based chemotherapy regimens are widely used, the effects of these agents have been limited. We have experienced a case that showed a partial response with sunitinib after failure of mitotane-based cytotoxic chemotherapy. The clinical benefit from sunitinib persisted 7.5 months in this case. To our knowledge, this is the first reported case showing the effects of sunitinib on metastatic ACC.

KW - Adrenocortical carcinoma

KW - Chemotherapy

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=61449181257&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyn146

DO - 10.1093/jjco/hyn146

M3 - Article

C2 - 19168875

AN - SCOPUS:61449181257

SN - 0368-2811

VL - 39

SP - 183

EP - 185

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

IS - 3

ER -

Metastatic adrenocortical carcinoma treated with sunitinib: A case report

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this